Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6451387 | 0.88 | ACACB (0.43) | L3MBTL1HTTRAB9ANPC1GAA | |
| SCHEMBL6451861 | 0.86 | TP53 (0.49) | L3MBTL1RAB9ANPC1GAASMN1; SMN2 | |
| SCHEMBL6448686 | 0.84 | CYP3A4 (0.44) | MAOAMAOBL3MBTL1RAB9ANPC1 | |
| SCHEMBL6452158 | 0.83 | CYP19A1 (0.46) | L3MBTL1ALOX15HTTRAB9AMEN1 | |
| SCHEMBL6449934 | 0.81 | ACACB (0.42) | L3MBTL1TSHRHTTRAB9AMEN1 | |
| SCHEMBL6453543 | 0.79 | NPC1 (0.46) | L3MBTL1USP2ALOX15TSHRRAB9A | |
| SCHEMBL6452697 | 0.79 | NPC1 (0.45) | L3MBTL1USP2TSHRRAB9AMEN1 | |
| SCHEMBL6448952 | 0.78 | TP53 (0.50) | L3MBTL1USP2ALOX15HTTRAB9A | |
| SCHEMBL6452535 | 0.77 | CASP3 (0.60) | L3MBTL1USP2ALOX15TSHRRAB9A | |
| SCHEMBL6448675 | 0.77 | NR1H4 (0.48) | L3MBTL1TSHRHTTRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | MAOA 1617/4885MAOB 1228/4885L3MBTL1 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.